Curaleaf Holdings (Curaleaf Holdings) ROCE % : 2.25% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Curaleaf Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Curaleaf Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was 2.25%.

Curaleaf Holdings ROCE % Historical Data

The historical data trend for Curaleaf Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaleaf Holdings ROCE % Chart

Curaleaf Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-3.58

7.19

5.72

0.08

-0.87

Curaleaf Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															2.44	-0.26	-1.81	-4.89	2.25

Curaleaf Holdings ROCE % Calculation

Curaleaf Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.984	/	( ( (3414.56 - 496.868)	+	(3096.576 - 494.034) )	/ 2 )
	=	-23.984	/	( (2917.692	+	2602.542)	/ 2 )
	=	-23.984	/	2760.117
	=	-0.87 %

Curaleaf Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	57.168	/	( ( (3096.576 - 494.034)	+	(3083.098 - 607.08) )	/ 2 )
	=	57.168	/	( ( 2602.542	+	2476.018 )	/ 2 )
	=	57.168	/	2539.28
	=	2.25 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Curaleaf Holdings (OTCPK:CURLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Curaleaf Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Curaleaf Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Curaleaf Holdings (Curaleaf Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaleaf Holdings Inc (OTCPK:CURLF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CURA:Canada

Address

420 Lexington Avenue, Suite 2035, New York, NY, USA, 10170-0052

Website

https://www.curaleaf.com

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.